(Q46674890)

24 December 2017

title

The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy (English)

1 reference

24 December 2017

1 reference

1 reference

1 reference

6

1 reference

24 December 2017

author name string

G J-H Park

1

1 reference

24 December 2017

P H Katelaris

2

1 reference

24 December 2017

D B Jones

3

1 reference

24 December 2017

F Seow

4

1 reference

24 December 2017

B P C Lin

5

1 reference

24 December 2017

M C Ngu

7

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

24 December 2017

Alimentary Pharmacology & Therapeutics

published in

1 reference

24 December 2017

volume

22

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

395-403

1 reference

24 December 2017

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Noninvasive diagnosis of hepatic fibrosis or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Drug disposition in patients with HBsAg-positive chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Value of AST/ALT ratio as fibrotic predictor in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Effect of smoking on caffeine clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

The absolute bioavailability of caffeine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Serum hyaluronan as a marker of liver fibrosis in asymptomatic chronic viral hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02623.X

10.1111/J.1365-2036.2005.02623.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017